As part of the NIH HEAL (Helping to End Addiction Long-termSM) Initiative, NCATS supports and facilitates a variety of funding, prize and collaboration opportunities designed to address the opioid crisis, including pain management.
- Current Funding Opportunities
- Translational Research Collaboration Opportunities
- Expired Funding Opportunities
- NOT-TR-19-018: HEAL Initiative: Announcement of Collaboration Opportunities for Developing Drugs and Human Cell-Based Testing Platforms for Pain, Addiction and Overdose
- NOT-TR-19-025: Notice of Change to HEAL Initiative: Announcement of Collaboration Opportunities for Developing Drugs and Human Cell-Based Testing Platforms for Pain, Addiction and Overdose
- NOT-TR-19-009: Notice of Correction to Revise Application Due Dates for NOT-TR-19-001 Notice of Availability of Administrative Supplements for Microphysiological Systems Developers: Development of Tissue Chips to Model Nociception, Opioid Addiction and Overdose
How do I:
- Translate my animal-based research discovery into a human-based model for continued testing and development?
- Advance my research on a potential therapeutic from plated cells into more complex, human cell-based models?
- Modify my compound to make it a drug?
- Collect the necessary data on my compound to advance towards testing in humans? What steps are involved?
Are these questions that you are wrestling with on your therapeutic development project? NCATS welcomes your HEAL-related proposals to advance promising compounds and human cell-based models through preclinical development as a team-based, research collaborations with NCATS’ intramural scientists in the Division of Preclinical Innovation.
- As research collaborators, you bring a wealth of background knowledge and a starting point for a particular translational project.
- NCATS scientists provide expertise and resources to transform those starting points into therapeutically useful tools, platforms, or investigational drugs.
- Approved projects result in formation of joint project teams that will work together to design and follow milestone-driven project plans to achieve pre-agreed to deliverables.
To view a presentation on how to collaborate with NCATS scientists, please go to 5:34:00 in the following video: https://videocast.nih.gov/Summary.asp?Live=31408&bhcp=1.
NOT-TR-19-018: HEAL Initiative: Announcement of Collaboration Opportunities for Developing Drugs and Human Cell-Based Testing Platforms for Pain, Addiction and Overdose
- RFA-TR-19-005: HEAL Initiative: Biofabricated 3D Tissue Models of Nociception, Opioid Use Disorder and Overdose for Drug Screening (UH2/UH3 Clinical Trial Not Allowed)
- RFA-TR-19-003: HEAL Initiative: Tissue Chips to Model Nociception, Addiction, and Overdose (UG3/UH3 Clinical Trial Not Allowed)
- NOT-TR-18-031: HEAL Initiative: Announcement of the NCATS ASPIRE Design Challenges to Develop Innovative and Catalytic Approaches Towards Solving the Opioid Crisis
ASPIRE Design Challenges Video: Learn about key dates, rules and requirements for participation from this informational applicant video.
The NIH HEAL Pain Management Effectiveness Research Network (NIH HEAL Pain Management ERN)
Using NCATS’ Clinical and Translational Science Awards Trial Innovation Network, the NIH HEAL Pain Management ERN will support studies to compare the effectiveness of existing pain treatments and novel approaches to prevent and manage pain while reducing the risk of addiction. The goal is to provide clinicians with information about the effectiveness of treatments or management strategies that reduce opioid use and pain associated with many types of diseases or conditions. Learn more about how the NIH HEAL Pain Management ERN will use the Trial Innovation Network for these studies.
- RFA-NS-19-021: HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
- NOT-NS-19-028: Notice of Change to Key Dates for RFA-NS-19-021 "HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)"